SEARCH RESULT

Total Matching Records found : 59

Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige

-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...

More »

Ranbaxy drugs safe says Australian drug regulator

-The Economic Times NEW DELHI: After the UK drug regulator, the Australian drug regulator has also said that the drugs marketed by Ranbaxy Labs are safe. "At present, there is no evidence that any of the products in the Australian market manufactured by Ranbaxy are of an unacceptable quality or that there is a danger to consumers in Australia," a spokesperson for the Australian Therapeutic Goods Administration (TGA) told ET. The Australian...

More »

United States finds pesticide residue in basmati, exports plunge -Madhvi Sally

-The Economic Times NEW DELHI: Basmati rice exports to the US have plunged because many Indian firms are under an import alert by the US authorities, leading to a detailed scrutiny for pesticide residue in every grain being shipped out. This has raised costs, upset schedules and obstructed sales, prompting exporters to seek government intervention. In the first quarter of calendar year 2013, exports were down to 19,583 tonne. With 31 Indian...

More »

Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan

-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...

More »

Indian drug makers face heat of US regulator's crackdown-Sushmi Dey

-The Business Standard Data also show that several other leading domestic pharma companies have recalled their products from the US Frequent drug recalls, warning letters and import alerts from the US in the recent past have turned into a major concern for the Indian pharmaceutical industry and investors. While Ranbaxy Laboratories recently pleaded guilty before the US authorities for its wrongdoings in the past, the crackdown on the drug companies seems to...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close